O	0	7	Alberta
B-intervention	8	16	physical
I-intervention	17	25	activity
O	26	29	and
O	30	36	breast
O	37	43	cancer
O	44	54	prevention
O	55	60	trial
O	60	61	:
O	62	65	sex
O	66	73	hormone
O	74	81	changes
O	82	84	in
O	85	86	a
O	87	91	year
O	91	92	-
O	92	96	long
O	97	105	exercise
O	106	118	intervention
O	119	124	among
O	125	139	postmenopausal
O	140	145	women
O	145	146	.

O	147	149	We
O	150	158	examined
O	159	162	how
O	163	165	an
O	166	173	aerobic
O	174	182	exercise
O	183	195	intervention
O	196	206	influenced
O	207	218	circulating
O	219	228	estradiol
O	228	229	,
O	230	237	estrone
O	237	238	,
O	239	242	sex
O	243	250	hormone
O	250	251	-
O	251	258	binding
O	259	267	globulin
O	268	269	(
O	269	273	SHBG
O	273	274	)
O	274	275	,
O	276	291	androstenedione
O	291	292	,
O	293	296	and
O	297	309	testosterone
O	310	316	levels
O	316	317	,
O	318	323	which
O	324	327	may
O	328	330	be
O	331	339	involved
O	340	342	in
O	343	346	the
O	347	358	association
O	359	366	between
O	367	375	physical
O	376	384	activity
O	385	388	and
O	389	395	breast
O	396	402	cancer
O	403	407	risk
O	407	408	.

O	409	410	A
O	411	414	two
O	414	415	-
O	415	421	center
O	421	422	,
O	423	426	two
O	426	427	-
O	427	430	arm
O	431	441	randomized
O	442	452	controlled
O	453	458	trial
O	459	461	of
O	462	470	exercise
O	471	474	was
O	475	484	conducted
O	485	487	in
B-total-participants	488	491	320
B-eligibility	492	506	postmenopausal
I-eligibility	506	507	,
I-eligibility	508	517	sedentary
I-eligibility	518	523	women
O	524	527	age
B-age	528	530	50
I-age	531	533	to
I-age	534	536	74
I-age	537	542	years
O	542	543	.

O	544	556	Participants
O	557	561	were
O	562	570	randomly
O	571	579	assigned
O	580	582	to
O	583	584	a
O	585	586	1
O	586	587	-
O	587	591	year
B-intervention	592	599	aerobic
I-intervention	600	608	exercise
O	609	621	intervention
O	622	624	of
O	625	628	225
O	629	632	min
O	632	633	/
O	633	635	wk
O	636	637	(
O	637	638	n
O	639	640	=
B-intervention-participants	641	644	160
O	644	645	)
O	646	648	or
O	649	651	to
O	652	653	a
O	654	661	control
O	662	667	group
O	668	671	who
O	672	682	maintained
O	683	688	their
B-control	689	694	usual
I-control	695	700	level
I-control	701	703	of
I-control	704	712	activity
O	713	714	(
O	714	715	n
O	716	717	=
B-control-participants	718	721	160
O	721	722	)
O	722	723	.

O	724	732	Baseline
O	732	733	,
O	734	735	6
O	735	736	-
O	736	741	month
O	741	742	,
O	743	746	and
O	747	749	12
O	749	750	-
O	750	755	month
O	756	767	assessments
O	768	770	of
O	771	778	estrone
O	778	779	,
O	780	789	estradiol
O	789	790	,
O	791	806	androstenedione
O	806	807	,
O	808	811	and
O	812	824	testosterone
O	825	829	were
O	830	840	quantified
O	841	843	by
O	844	860	radioimmunoassay
O	861	866	after
O	867	877	extraction
O	877	878	,
O	879	882	and
O	883	887	SHBG
O	888	891	was
O	892	902	quantified
O	903	905	by
O	906	908	an
O	909	921	immunometric
O	922	927	assay
O	927	928	.

O	929	935	Intent
O	935	936	-
O	936	938	to
O	938	939	-
O	939	944	treat
O	945	953	analyses
O	954	958	were
O	959	968	performed
O	969	974	using
O	975	981	linear
O	982	987	mixed
O	988	994	models
O	994	995	.

O	996	1001	Blood
O	1002	1006	data
O	1007	1011	were
O	1012	1021	available
O	1022	1024	on
B-total-participants	1025	1028	309
O	1029	1034	women
O	1035	1036	(
O	1036	1038	96
O	1038	1039	.
O	1039	1040	6
O	1040	1041	%
O	1041	1042	)
O	1043	1045	at
O	1046	1048	12
O	1049	1055	months
O	1055	1056	.

O	1057	1062	Women
O	1063	1065	in
O	1066	1069	the
O	1070	1082	intervention
O	1083	1088	group
O	1089	1098	exercised
O	1099	1101	an
O	1102	1109	average
O	1110	1112	of
O	1113	1114	3
O	1114	1115	.
O	1115	1116	6
O	1117	1118	d
O	1118	1119	/
O	1119	1121	wk
O	1122	1125	for
O	1126	1129	178
O	1130	1133	min
O	1133	1134	/
O	1134	1136	wk
O	1136	1137	.

O	1138	1140	At
O	1141	1143	12
O	1144	1150	months
O	1150	1151	,
O	1152	1165	statistically
B-outcome	1166	1177	significant
I-outcome	1178	1188	reductions
I-outcome	1189	1191	in
I-outcome	1192	1201	estradiol
O	1202	1203	(
O	1203	1212	treatment
O	1213	1219	effect
O	1220	1225	ratio
O	1226	1227	[
O	1227	1230	TER
O	1230	1231	]
O	1232	1233	=
O	1234	1235	0
O	1235	1236	.
O	1236	1238	93
O	1238	1239	;
O	1240	1242	95
O	1242	1243	%
O	1244	1246	CI
O	1246	1247	,
O	1248	1249	0
O	1249	1250	.
O	1250	1252	88
O	1253	1255	to
O	1256	1257	0
O	1257	1258	.
O	1258	1260	98
O	1260	1261	)
O	1262	1265	and
B-outcome	1266	1270	free
I-outcome	1271	1280	estradiol
O	1281	1282	(
O	1282	1285	TER
O	1286	1287	=
O	1288	1289	0
O	1289	1290	.
O	1290	1292	91
O	1292	1293	;
O	1294	1296	95
O	1296	1297	%
O	1298	1300	CI
O	1300	1301	,
O	1302	1303	0
O	1303	1304	.
O	1304	1306	87
O	1307	1309	to
O	1310	1311	0
O	1311	1312	.
O	1312	1314	96
O	1314	1315	)
O	1316	1319	and
B-outcome	1320	1329	increases
I-outcome	1330	1332	in
I-outcome	1333	1337	SHBG
O	1338	1339	(
O	1339	1342	TER
O	1343	1344	=
O	1345	1346	1
O	1346	1347	.
O	1347	1349	04
O	1349	1350	;
O	1351	1353	95
O	1353	1354	%
O	1355	1357	CI
O	1357	1358	,
O	1359	1360	1
O	1360	1361	.
O	1361	1363	02
O	1364	1366	to
O	1367	1368	1
O	1368	1369	.
O	1369	1371	07
O	1371	1372	)
O	1373	1377	were
O	1378	1386	observed
O	1387	1389	in
O	1390	1393	the
O	1394	1402	exercise
O	1403	1408	group
O	1409	1417	compared
O	1418	1422	with
O	1423	1426	the
O	1427	1434	control
O	1435	1440	group
O	1440	1441	.

B-outcome	1442	1444	No
I-outcome	1445	1456	significant
I-outcome	1457	1468	differences
I-outcome	1469	1471	in
I-outcome	1472	1479	estrone
I-outcome	1479	1480	,
I-outcome	1481	1496	androstenedione
I-outcome	1496	1497	,
I-outcome	1498	1501	and
I-outcome	1502	1514	testosterone
I-outcome	1515	1521	levels
O	1522	1526	were
O	1527	1535	observed
O	1536	1543	between
O	1544	1554	exercisers
O	1555	1558	and
O	1559	1567	controls
O	1568	1570	at
O	1571	1573	12
O	1574	1580	months
O	1580	1581	.

O	1582	1586	This
O	1587	1592	trial
O	1593	1598	found
O	1599	1603	that
O	1604	1614	previously
O	1615	1624	sedentary
O	1625	1639	postmenopausal
O	1640	1645	women
O	1646	1649	can
O	1650	1656	adhere
O	1657	1659	to
O	1660	1661	a
O	1662	1670	moderate
O	1670	1671	-
O	1672	1674	to
O	1675	1683	vigorous
O	1683	1684	-
O	1684	1693	intensity
O	1694	1702	exercise
O	1703	1710	program
O	1711	1715	that
O	1716	1723	results
O	1724	1726	in
O	1727	1734	changes
O	1735	1737	in
O	1738	1747	estradiol
O	1748	1751	and
O	1752	1756	SHBG
O	1757	1771	concentrations
O	1772	1776	that
O	1777	1780	are
O	1781	1791	consistent
O	1792	1796	with
O	1797	1798	a
O	1799	1804	lower
O	1805	1809	risk
O	1810	1813	for
O	1814	1828	postmenopausal
O	1829	1835	breast
O	1836	1842	cancer
O	1842	1843	.
